BRPI0912802A2 - ativadores de glicoquinase - Google Patents

ativadores de glicoquinase

Info

Publication number
BRPI0912802A2
BRPI0912802A2 BRPI0912802A BRPI0912802A BRPI0912802A2 BR PI0912802 A2 BRPI0912802 A2 BR PI0912802A2 BR PI0912802 A BRPI0912802 A BR PI0912802A BR PI0912802 A BRPI0912802 A BR PI0912802A BR PI0912802 A2 BRPI0912802 A2 BR PI0912802A2
Authority
BR
Brazil
Prior art keywords
glycokinase activators
glycokinase
activators
Prior art date
Application number
BRPI0912802A
Other languages
English (en)
Inventor
Andrew John Jennings
Haxia Wang
Jeffrey A Stafford
Mark Sabat
Mingnam Tang
Stephen L Gwaltney
Zacharia Cheruvallath
Original Assignee
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41076813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912802(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda San Diego Inc filed Critical Takeda San Diego Inc
Publication of BRPI0912802A2 publication Critical patent/BRPI0912802A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0912802A 2008-05-16 2009-05-15 ativadores de glicoquinase BRPI0912802A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5405208P 2008-05-16 2008-05-16
US10837008P 2008-10-24 2008-10-24
PCT/US2009/044190 WO2009140624A2 (en) 2008-05-16 2009-05-15 Glucokinase activators

Publications (1)

Publication Number Publication Date
BRPI0912802A2 true BRPI0912802A2 (pt) 2015-10-13

Family

ID=41076813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912802A BRPI0912802A2 (pt) 2008-05-16 2009-05-15 ativadores de glicoquinase

Country Status (27)

Country Link
US (4) US8563730B2 (pt)
EP (1) EP2294053B1 (pt)
JP (1) JP5513492B2 (pt)
KR (1) KR20110018366A (pt)
CN (1) CN102105451B (pt)
AR (1) AR071811A1 (pt)
AU (1) AU2009246167B2 (pt)
BR (1) BRPI0912802A2 (pt)
CA (1) CA2724116A1 (pt)
CL (1) CL2009001203A1 (pt)
CO (1) CO6321274A2 (pt)
CR (1) CR11827A (pt)
DO (1) DOP2010000351A (pt)
EA (1) EA018988B1 (pt)
EC (1) ECSP10010688A (pt)
GE (1) GEP20135783B (pt)
IL (1) IL209062A (pt)
MA (1) MA32391B1 (pt)
MX (1) MX2010012298A (pt)
MY (1) MY152749A (pt)
NZ (1) NZ589084A (pt)
PE (2) PE20141375A1 (pt)
SG (1) SG190625A1 (pt)
TW (1) TWI445707B (pt)
UY (1) UY31830A (pt)
WO (1) WO2009140624A2 (pt)
ZA (1) ZA201007975B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835377B (zh) 2007-08-27 2014-12-10 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
US20100330177A1 (en) * 2008-02-05 2010-12-30 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
KR20110018366A (ko) 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
UA105185C2 (uk) 2008-08-27 2014-04-25 Такеда Фармасьютікал Компані Лімітед Піроли
AU2009290474A1 (en) * 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
KR101364869B1 (ko) 2008-09-24 2014-02-21 바스프 에스이 무척추　해충을　방제하기　위한　피라졸　화합물
ES2461618T3 (es) 2009-07-06 2014-05-20 Basf Se Compuestos de piridacina para el control de plagas de invertebrados
EP2451804B1 (en) 2009-07-06 2014-04-30 Basf Se Pyridazine compounds for controlling invertebrate pests
JP2013500246A (ja) 2009-07-24 2013-01-07 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリジン誘導体化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
NZ603614A (en) * 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103328471A (zh) * 2010-10-13 2013-09-25 武田加利福尼亚股份有限公司 制备氮杂吲唑衍生物的方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014028622A2 (pt) 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
CN105050585A (zh) * 2013-03-04 2015-11-11 Vtv治疗有限责任公司 稳定的葡萄糖激酶活化剂组合物
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG10201912805SA (en) * 2014-12-19 2020-02-27 Aragon Pharmaceuticals Inc Process for the preparation of a diarylthiohydantoin compound
CN105092770B (zh) * 2015-01-12 2017-03-29 上海中医药大学 一种筛选二肽基肽酶四抑制剂的方法
EP3307706B1 (en) 2015-06-15 2019-07-24 Bayer CropScience AG Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
HUE051950T2 (hu) 2015-06-15 2021-04-28 Bayer Cropscience Ag Halogén-szubsztituált fenoxifenilamidinok és alkalmazásuk fungicidként
WO2018109002A1 (en) 2016-12-14 2018-06-21 Bayer Cropscience Aktiengesellschaft Active compound combinations
EP3335559A1 (en) 2016-12-14 2018-06-20 Bayer CropScience Aktiengesellschaft Active compound combinations
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
AU2019278015B2 (en) * 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9315846D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tumour inhibitors
US5795726A (en) 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
PL350669A1 (en) 1999-03-29 2003-01-27 Hoffmann La Roche Glucokinase activators
US20030013633A1 (en) 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
HUP0600522A2 (en) 1999-12-23 2006-11-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
DE60111534T2 (de) 2000-07-20 2006-05-11 F. Hoffmann-La Roche Ag Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
US7358267B2 (en) 2001-06-29 2008-04-15 Amgen Inc. Bis-aryl thiazole derivatives
JP2005526702A (ja) 2001-12-03 2005-09-08 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニストとの組み合わせにおける２型糖尿病治療のためのグルコキナーゼ活性化剤の使用
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
GB0216097D0 (en) 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
JP2006508939A (ja) 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
DE60336850D1 (en) 2003-01-06 2011-06-01 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7179613B2 (en) 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005052132A2 (en) 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
US20080026987A1 (en) 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
KR20070034591A (ko) 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
KR100890695B1 (ko) 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
WO2006024492A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
WO2006080524A1 (ja) 2005-01-31 2006-08-03 Ajinomoto Co., Inc. 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
JP2009501513A (ja) 2005-06-22 2009-01-22 メルク エンド カムパニー インコーポレーテッド Ｈｃｖ複製阻害の標的
US7565029B2 (en) * 2005-07-08 2009-07-21 Seiko Epson Corporation Method for determining camera position from two-dimensional images that form a panorama
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
WO2007026761A1 (ja) 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
EP2118083A1 (en) 2007-01-09 2009-11-18 Novo Nordisk A/S Urea glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US20100183514A1 (en) 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2009022179A2 (en) 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
KR20110018366A (ko) 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
US20130281708A1 (en) 2010-03-18 2013-10-24 Takeda California, Inc. Process for the Production of 2-Amino-5-Fluorothiazole
CN103328471A (zh) 2010-10-13 2013-09-25 武田加利福尼亚股份有限公司 制备氮杂吲唑衍生物的方法

Also Published As

Publication number Publication date
MY152749A (en) 2014-11-28
US20090286800A1 (en) 2009-11-19
MA32391B1 (fr) 2011-06-01
CA2724116A1 (en) 2009-11-19
PE20091901A1 (es) 2010-01-06
AU2009246167A2 (en) 2010-12-16
CL2009001203A1 (es) 2009-10-23
AR071811A1 (es) 2010-07-14
WO2009140624A3 (en) 2010-05-27
EP2294053A2 (en) 2011-03-16
IL209062A0 (en) 2011-01-31
AU2009246167A1 (en) 2009-11-19
EA018988B1 (ru) 2013-12-30
KR20110018366A (ko) 2011-02-23
US20140045859A1 (en) 2014-02-13
US20120225887A1 (en) 2012-09-06
IL209062A (en) 2015-08-31
SG190625A1 (en) 2013-06-28
EA201071320A1 (ru) 2011-06-30
CR11827A (es) 2011-03-09
US9139598B2 (en) 2015-09-22
AU2009246167B2 (en) 2013-08-22
CN102105451B (zh) 2013-11-13
UY31830A (es) 2010-01-05
ECSP10010688A (es) 2011-04-29
WO2009140624A2 (en) 2009-11-19
GEP20135783B (en) 2013-03-11
EP2294053B1 (en) 2016-01-06
DOP2010000351A (es) 2011-02-15
CN102105451A (zh) 2011-06-22
ZA201007975B (en) 2012-02-29
JP5513492B2 (ja) 2014-06-04
TW200948809A (en) 2009-12-01
JP2011520915A (ja) 2011-07-21
US20160009735A1 (en) 2016-01-14
MX2010012298A (es) 2011-03-15
CO6321274A2 (es) 2011-09-20
TWI445707B (zh) 2014-07-21
NZ589084A (en) 2012-06-29
PE20141375A1 (es) 2014-10-23
US8563730B2 (en) 2013-10-22

Similar Documents

Publication Publication Date Title
BRPI0912802A2 (pt) ativadores de glicoquinase
BRPI0815557A2 (pt) Atividaores de glicocinase
BRPI0907925A2 (pt) Ativadores de glicoquinase.
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2342454T3 (da) Vindkraftanlæg
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
EP2308156A4 (en) STEP ACTUATOR
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
DE602008003970D1 (de) Strahlstromkalibriersystem
EP2257170A4 (en) TETRAHYDROFUROPYRIDONE
EP2248964A4 (en) DRILLING / TERMINAL DEVICE
EP2318641A4 (en) TOOL FOR CENTERING FOR DRILLING ENCLOSURE
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA CALIFORNIA, INC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]